30 December 2014 : Original article
Nedaplatin or Oxaliplatin Combined with Paclitaxel and Docetaxel as First-Line Treatment for Patients with Advanced Non-Small Cell Lung CancerKeqian ZhangABD, Hong QinBCDEF, Feng PanBC, Enqiang LiuBC, Houjie LiangAD, Zhihua RuanAD
Med Sci Monit 2014; 20:2830-2836
BACKGROUND: Both nedaplatin and oxaliplatin combined with paclitaxel or docetaxel have demonstrated potent activity in advanced non-small cell lung cancer (NSCLC) patients, but there is no study comparing the difference between these 2 chemotherapy regimens. The aim of this study was to evaluate and compare the efficacy and safety between the combination chemotherapy of nedaplatin or oxaliplatin plus paclitaxel and docetaxel in patients with advanced NSCLC.
MATERIAL AND METHODS: We retrospectively reviewed patients with stage III-IV unresectable NSCLC from 1 January 2010 to 31 December 2013 at Southwest Hospital. They all received nedaplatin (80 mg/m2, nedaplatin group) or oxaliplatin (130 mg/m2, oxaliplatin group) combined with paclitaxel (175 mg/m2) or docetaxel (75 mg/m2) as first-line treatment.
RESULTS: There are 174 patients enrolled – 123 patients in the nedaplatin group and 51 patients in the oxaliplatin group. The objective response rates were 47.3% and 34.1% and the disease control rates were 87.5% and 79.5% in nedaplatin and oxaliplatin groups, respectively. The progression-free survival time was 10.4 months and 9.6 months (p=0.722) and the overall survival time was 18.5 months and 25.5 months in the nedaplatin and oxaliplatin groups, respectively (p=0.09). Total toxicity was greater in the oxaliplatin group (p=0.008), but there is no significant difference among ¾ grade adverse events between the 2 groups (P=0.595).
CONCLUSIONS: The effect of nedaplatin plus paclitaxel and docetaxel is the same as oxaliplatin plus paclitaxel and docetaxel, and the toxicity of nedaplatin is well tolerate as first-line treatment for patients with advanced NSCLC.
Keywords: Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Carcinoma, Non-Small-Cell Lung - pathology, Disease-Free Survival, Lung Neoplasms - pathology, Neoplasm Staging, Organoplatinum Compounds - therapeutic use, Paclitaxel - therapeutic use, Taxoids - therapeutic use
This Week Editorial
02 August 2021 : EditorialEditorial: The National COVID Cohort Collaborative Consortium Combines Population Data with Machine Learning to Evaluate and Predict Risk Factors for the Severity of COVID-19
Med Sci Monit 2021; 27:e934171
30 July 2021 : Clinical ResearchRural and Female Patients with Old Myocardial Infarction Lacked Knowledge and Preventive Measures During th...
Med Sci Monit In Press :: DOI: 10.12659/MSM.928512
16 July 2021 : Review articleSilent Hypoxemia in Patients with COVID-19 Pneumonia: A Review
Med Sci Monit In Press :: DOI: 10.12659/MSM.930776
09 July 2021 : Database AnalysisA Simple Clinical Prediction Tool for COVID-19 in Primary Care with Epidemiology: Temperature-Leukocytes-CT...
Med Sci Monit In Press :: DOI: 10.12659/MSM.931467
03 Aug 2021 : Clinical ResearchComparison of Outcomes Following TiRobot-Assisted Sacroiliac Screw Fixation with Bone Grafting and Traditio...
Med Sci Monit In Press :: DOI: 10.12659/MSM.932724
02 Aug 2021 : Database AnalysisRNA N6-Methyladenosine Patterns in Hepatocellular Carcinoma Reveal a Distinct Immune Infiltration Landscape...
Med Sci Monit In Press :: DOI: 10.12659/MSM.930994
02 Aug 2021 : Clinical ResearchVitamin D Receptor Is a Sepsis-Susceptibility Gene in Chinese Children
Med Sci Monit In Press :: DOI: 10.12659/MSM.932518
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700